Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.75 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.75 |
| ▸ | F3 | P13726 | 4/20 | 0.75 |
| ▸ | POLB | P06746 | 3/20 | 0.75 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.75 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.75 |
| ▸ | USP7 | Q93009 | 3/20 | 0.75 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.75 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.75 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.75 |
| ▸ | PTPRC | P08575 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumaresinolic Acid SCHEMBL12447712 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2TDP1KDM4EALDH1A1 | |
| Sumaresinolic Acid SCHEMBL15382986 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2TDP1KDM4EALDH1A1 | |
| SCHEMBL12447463 | 0.90 | CYP3A4 (0.81) | CYP3A4USP2TDP1KDM4EALDH1A1 | |
| Oleanolic_Acid SCHEMBL13425080 | 0.86 | PTPN1 (1.00) | CYP3A4USP2PTPN1PTPN2F3 | |
| Oleanolic_Acid SCHEMBL21892159 | 0.86 | PTPN1 (1.00) | CYP3A4USP2PTPN1PTPN2F3 | |
| Oleanolic_Acid SCHEMBL24916648 | 0.86 | PTPN1 (1.00) | CYP3A4USP2PTPN1PTPN2F3 | |
| Oleanolic_Acid SCHEMBL22009261 | 0.86 | PTPN1 (1.00) | CYP3A4USP2PTPN1PTPN2F3 | |
| Oleanolic_Acid SCHEMBL20904290 | 0.86 | PTPN1 (1.00) | CYP3A4USP2PTPN1PTPN2F3 | |
| Oleanolic_Acid SCHEMBL15714063 | 0.86 | PTPN1 (1.00) | CYP3A4USP2PTPN1PTPN2F3 | |
| Oleanolic_Acid SCHEMBL13395360 | 0.86 | PTPN1 (1.00) | CYP3A4USP2PTPN1PTPN2F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168230-A1 | NANOPARTICLE MEDIATED THERAPY | YALE UNIVERSITY | 2022-06-02 | — | — | US | disclosed |
| US-20200214989-A1 | NANOMATERIALS WITH ENHANCED DRUG DELIVERY EFFICIENCY | YALE UNIVERSITY | 2020-07-09 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CACYBP, TBCB, MYCBP | CYP3A4 3998/4885USP2 2888/4885TDP1 2275/4885 |
| US-20200214989-A1 | NANOMATERIALS WITH ENHANCED DRUG DELIVERY EFFICIENCY | VIP, SI, LSS | CYP3A4 2460/4885USP2 3661/4885TDP1 4873/4885 |
| US-20220168230-A1 | NANOPARTICLE MEDIATED THERAPY | LSS, CYP46A1, CYP51A1 | CYP3A4 1445/4885USP2 4856/4885TDP1 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.